Shed syndecan-1 inhibits myeloma cell growth: A mechanism of autocrine growth control in multiple myeloma.

被引：0
|
作者：
Dhodapkar, M
Theus, A
Langford, K
Butch, A
Barlogie, B
Sanderson, R
机构：
[1] UNIV ARKANSAS,LITTLE ROCK,AR 72204
[2] VAMC,LITTLE ROCK,AR
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：395 / 395
页数：1
相关论文
共 50 条
  • [1] Syndecan-1 is essential for the myeloma cell growth factor activity of EGF-family ligands in multiple myeloma.
    Mahtouk, K
    Cremer, FW
    Rème, T
    Jourdan, M
    Baudard, M
    Moreaux, M
    Requirand, G
    Fiol, G
    De Vos, J
    Moos, M
    Quittet, P
    Goldschmidt, H
    Rossi, JF
    Hose, D
    Klein, B
    BLOOD, 2005, 106 (11) : 186A - 186A
  • [2] Soluble syndecan-1 is a prognostic marker in multiple myeloma.
    Jánosi, J
    Sebestyén, A
    Mikala, G
    Petö, M
    Jákó, J
    Domján, G
    Németh, R
    Kiss, Z
    Kopper, L
    Vályi-Nagy, I
    BLOOD, 2003, 102 (11) : 362B - 362B
  • [3] Shed syndecan-1 mediates aggregation and spreading of myeloma cells
    Stanley, MJ
    Liu, W
    Lander, AD
    Sanderson, RD
    MOLECULAR BIOLOGY OF THE CELL, 1997, 8 : 2283 - 2283
  • [4] Disseminated growth of myeloma tumors is regulated by heparanase and syndecan-1
    Khotskaya, Yekaterina
    Suva, Larry
    Sanderson, Ralph
    CANCER RESEARCH, 2009, 69
  • [5] Soluble syndecan-1 promotes growth of myeloma tumors in vivo
    Yang, Y
    Yaccoby, S
    Liu, W
    Langford, JK
    Pumphrey, CY
    Theus, A
    Epstein, J
    Sanderson, RD
    BLOOD, 2002, 100 (02) : 610 - 617
  • [6] Longitudinal study of serum vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and syndecan-1 in patients with multiple myeloma.
    Kyrtsonis, MC
    Siakantaris, MP
    Vassilakopoulos, TP
    Kokoris, SL
    Giannakakis, A
    Angelopoulou, MK
    Pangalis, GA
    BLOOD, 2001, 98 (11) : 299B - 299B
  • [7] Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation
    Dhodapkar, MV
    Abe, E
    Theus, A
    Lacy, M
    Langford, JK
    Barlogie, B
    Sanderson, RD
    BLOOD, 1998, 91 (08) : 2679 - 2688
  • [8] Binding of TACI and APRIL to syndecan-1 confer on them a major role in multiple myeloma.
    Moreaux, Jerome
    Sprynski, Anne-Catherine
    Mahtouk, Karene
    Moine, Philippe
    Robert, Nicolas
    Rossi, Jean-Francois
    Klein, Bernard
    BLOOD, 2007, 110 (11) : 1031A - 1031A
  • [9] Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions
    Bayer-Garner, IB
    Sanderson, RD
    Dhodapkar, MV
    Owens, RB
    Wilson, CS
    MODERN PATHOLOGY, 2001, 14 (10) : 1052 - 1058
  • [10] Soluble syndecan-1 modulates myeloma growth but not through FGF signalling
    Lovell, RA
    Guimond, SE
    Turnbull, JE
    Moss, PAH
    Pratt, G
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 : 9 - 9
12345